P&K Skin Clinical Research Center Reports 20% Increase in Q1 Operating Profit Compared to Previous Quarter... "Expecting Strong Performance from Q2 Onwards"

[Asia Economy Reporter Hyunseok Yoo] P&K Skin Clinical Research Center (hereinafter P&K) announced on the 17th that it recorded sales of 4 billion KRW, operating profit of 1.8 billion KRW, and net profit of 2 billion KRW in the first quarter. These figures represent increases of 20%, 81%, and 92% respectively compared to the previous quarter.

A P&K official stated, “Despite the social distancing level 2 measures in Seoul due to COVID-19 during the first quarter, the results increased by 20% compared to the previous quarter, signaling a smooth start for the company’s management. Since the first quarter of last year had almost no impact from COVID-19, this year’s first quarter performed well despite the pandemic situation.”

Regarding future performance outlook, the P&K official said, “With the sales from the Bupyeong Dream Center, which opened last March, being fully reflected in the results from the second quarter onward, we are looking forward to improved performance after the second quarter. Requests from cosmetic manufacturers and health supplement companies are increasing, so we expect further growth in performance.” He added, “Lastly, regarding the highly anticipated entry into the Chinese market, we are proceeding with the planned procedures and are doing our best to establish a corporation in the second half of this year.”

P&K opened the Dream Center in Bupyeong last March, securing 170% of the existing CAPA, and began full-scale operations from April.

This content was produced with the assistance of AI translation services.